Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
This phase I study plan is divided in the following four phases: - Eligibility Screen Phase (week -4 to -1): Following written informed consent patients with metastatic melanoma (AJCC stage III/IV with unresectable disease) will undergo an eligibility screen (incl. blood analysis and PET/CT-scan). - TriMix-DC Vaccine Manufacturing Phase (week I to IV): eligible patients will undergo a leucapheresis (15 liter of venous blood) for the preparation of autologous TriMix-DC vaccine. Vaccine preparations will be manufactured and quality-controlled (during an interval of 4 weeks following the leucapheresis) and released for patient administration if the TriMix-DC preparation fulfills the predefined quality requirements. - TriMix-DC Vaccine Administration Phase (Week 1 to 24): 4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks. At each vaccination a total of 12.106 DC per antigen will be administered. - Patients will be allocated to three different cohorts: - The first cohort will receive 10% of TriMix-DC by iv and 90% by id injection. - The second cohort 25% by iv and 75% by id injection. - The third cohort 50% by iv and 50% by id injection. - During the week following the administration of the fourth vaccine (= week 8), a DTH-test and punch biopsy of the injection site will be performed as well as a second leucapheresis (for the purpose of immuno-monitoring) and tumor evaluation (by PET-CT). - A fifth vaccine will be administered and a repeat tumor staging performed in week 16 (= 8w after the fourth vaccine). - End of study visit: Patients will perform an "end of study visit" 8 weeks after the fifth vaccine (= week 24) as well as a new tumor evaluation (PET/CT). - Follow-up Phase: survival data will be obtained until 3 years after the initiation of vaccine therapy or the time of death.
Critère d'inclusion
- Melanoma